The global helicobacter pylori diagnostics market revenue was around US$ 581.9 million in 2023 and is estimated to reach US$ 926.3 million by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period from 2024 to 2032.
Gastritis and peptic ulcer disease are just two gastrointestinal conditions linked to the stomach infection Helicobacter pylori (H. pylori). The breath test, stool antigen test, and rapid urease test are a few ways to diagnose an H. pylori infection. One kind of bacteria that can infect the stomach and small intestine is called Helicobacter pylori, or H. pylori. Two-thirds of people worldwide are thought to be afflicted with this widespread bacterial infection. Gastritis (inflammation of the stomach lining), peptic ulcers (sores in the stomach or duodenum), and in rare instances, stomach cancer are among the gastrointestinal issues brought on by H. pylori. Weight loss, nausea, vomiting, loss of appetite, and abdominal pain are typical signs of an H. pylori infection.
Factors Influencing Market Growth
- The demand for H. pylori diagnostic testing is driven by the increase in gastric cancer cases, which further fuels market expansion.
- demand for non-invasive tests has driven the development of new diagnostic technologies which is increasing the demand for H. pylori diagnostic testing thus propelling the market growth.
- Due to the growing demand for better healthcare services, large government investments in infrastructure improvements, and the growth of the medical tourism sector in emerging nations, the healthcare industry in emerging economies is expanding quickly. this is increasing the demand for H. pylori diagnostic testing thus expanding the market.
- Lack of awareness about the H. pylori infection among the general population may hinder market growth.
Impact of COVID-19
COVID-19 negatively impacted the market. Globally, COVID-19 has interrupted healthcare workers' workflows. Numerous industries, including some healthcare industry segments, have been forced to close their doors due to the disease temporarily. The COVID-19-driven worldwide economic downturn in 2021 caused a decline in the helicobacter pylori diagnostics market. The COVID-19 pandemic has caused non-urgent diagnostic procedures such as H. pylori testing to be postponed or canceled. As a result, there is less of a need for H. pylori testing, which has had an impact on the earnings of businesses in this industry. Additionally, the pandemic also resulted in fewer patient visits to medical facilities because of social distancing measures and fear of infection. This harmed the market by lowering the number of patients having H. pylori testing.
Regional Insights
North America dominated the market in 2023. This is because the area has the highest healthcare spending, which makes it possible for patients to have better access to H. pylori testing and diagnosis tests, which is anticipated to support market expansion. Moreover, the market is anticipated to grow due to the existence of a well-established healthcare infrastructure, high purchasing power, and an increase in the rate of Helicobacter pylori diagnostic test adoption. Additionally, the key players in this region's product approvals, acquisitions, and agreements all contribute to the market's growth.
Leading Competitors
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Avanos Medical, Inc.
- Quidel Corporation
- Cardinal Health Inc.
- Biohit Oyj
- Meridian Bioscience, Inc.
- Bio-Rad Laboratories, Inc.
- Gulf Coast Scientific
- Other Prominent Players
Segmentation Analysis
The global helicobacter pylori diagnostics market segmentation focuses on test type, method, end user, and region.
Segmentation based on Test Type
- Non-Invasive Test
- Serology Test
- Stool Antigen Test
- Carbon Urea Breath Test
- Invasive Test
Segmentation based on Method
- Laboratory Based Test
- Point of Care Test
Segmentation based on End User
- Diagnostics Laboratories
- Others
- Hospitals
Segmentation based on Region
- North America
- The U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Netherlands
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Rest Of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa